Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 2/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | DBH | P09172 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | AGXT | P21549 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5487052 | 1.00 | IDO1 (0.46) | IDO1CA12CA1CA9TRPA1 | |
| SCHEMBL5733912 | 1.00 | IDO1 (0.46) | IDO1CA12CA1CA9TRPA1 | |
| SCHEMBL11029571 | 0.97 | IDO1 (0.44) | IDO1CA12CA1CA9TRPA1 | |
| Pentane SCHEMBL28136158 | 0.85 | IDO1 (0.37) | IDO1TSHR | |
| SCHEMBL29472374 | 0.84 | IDO1 (0.34) | IDO1TRPA1ALDH1A1TSHR | |
| SCHEMBL671058 | 0.84 | IDO1 (0.34) | IDO1TRPA1ALDH1A1TSHR | |
| SCHEMBL25077209 | 0.82 | IDO1 (0.38) | IDO1TAAR1 | |
| SCHEMBL2924850 | 0.82 | ACHE (0.36) | IDO1 | |
| SCHEMBL857310 | 0.82 | DAO (0.37) | IDO1TSHRDAO | |
| SCHEMBL20503990 | 0.82 | IDO1 (0.33) | IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1323 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119954778-A | Synthesis method of lenacipam sodium and series of intermediate compounds thereof | 杭州科巢生物科技有限公司 | 2025-05-09 | — | — | CN | claimed |
| CN-119031729-A | Perovskite solar cell for regulating perovskite crystallization by 3, 5-difluorobenzyl bromide, perovskite-based laminated solar cell and preparation method | 中国长江三峡集团有限公司 | 2024-11-26 | — | — | CN | claimed |
| CN-115785080-B | Uracil parent nucleus compound and preparation method and application thereof | 陕西盘龙药业集团股份有限公司 | 2024-10-11 | — | — | CN | claimed |
| CN-118063504-A | Fluoro phenyl phosphate compound, perovskite thin film, perovskite solar cell, preparation method, electric equipment and application | 天合光能股份有限公司 | 2024-05-24 | — | — | CN | claimed |
| CN-115232126-B | Beta-carbolin-1, 2, 3-triazole compound, preparation method thereof and application of compound in resisting Alzheimer disease | 中国人民解放军北部战区总医院 | 2023-04-25 | — | — | CN | claimed |
| CN-115232126-A | Beta-carbopol-1, 2, 3-triazole compound, preparation method thereof and application thereof in resisting Alzheimer disease | 中国人民解放军北部战区总医院 | 2022-10-25 | — | — | CN | claimed |
| EP-3752496-A1 | METHODS AND INTERMEDIATES FOR PREPARING A THERAPEUTIC COMPOUND USEFUL IN THE TREATMENT OF RETROVIRIDAE VIRAL INFECTION | GILEAD SCIENCES, INC. (US) | 2020-12-23 | — | — | EP | claimed |
| CN-112055712-A | Processes and intermediates for preparing therapeutic compounds useful in the treatment of retroviral infections | 吉利德科学公司 | 2020-12-08 | — | — | CN | claimed |
| WO-2019161280-A1 | METHODS AND INTERMEDIATES FOR PREPARING A THERAPEUTIC COMPOUND USEFUL IN THE TREATMENT OF RETROVIRIDAE VIRAL INFECTION | GILEAD SCIENCES, INC. (US) | 2019-08-22 | — | — | WO | claimed |
| EP-1622907-A1 | AZABICYCLONONENE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2006-02-08 | — | — | EP | claimed |
| WO-2004096803-A1 | AZABICYCLONONENE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2004-11-11 | — | — | WO | claimed |
| CN-116854630-B | Methods and intermediates for preparing therapeutic compounds useful in the treatment of retroviral infections | 吉利德科学公司 | 2026-05-19 | — | — | CN | disclosed |
| EP-4737448-A1 | SARM1 ENZYME ACTIVITY INHIBITOR AND USE THEREOF | Artivila (ShenZhen) Innovation Center, Ltd. (CN) | 2026-05-06 | — | — | EP | disclosed |
| EP-4736882-A2 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | Cullgen (Shanghai), Inc. (CN) | 2026-05-06 | — | — | EP | disclosed |
| US-12570675-B2 | Boronic acid compounds | LG CHEM, LTD. (KR) | 2026-03-10 | — | — | US | disclosed |
| US-5387593-A | Anxiolytic agents | BRISTON-MYERS SQUIBB (US) | 1995-02-07 | — | — | US | disclosed |
| US-5380729-A | Treatment or prevention of neurodegenerative disorders or neurotoxic injuries | STERLING WINTHROP INC. (US) | 1995-01-10 | — | — | US | disclosed |
| EP-0629604-A2 | Alicyclic phospholipase A2 inhibitors | Bristol-Myers Company (US) | 1994-12-21 | — | — | EP | disclosed |
| WO-1994024130-A1 | NEW PYRIDINIUM SALTS AND THEIR USE FOR CONTROLLING HELICOBACTER BACTERIA | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1994-10-27 | — | — | WO | disclosed |
| EP-0546583-A1 | Piperazinyl-and piperidinyl-cyclohexanols | Bristol-Myers Squibb Company (US) | 1993-06-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570675-B2 | Boronic acid compounds | PSMB6, PSMB3, PSMB2 | IDO1 3016/4885CA12 381/4885CA1 477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.